富含二酰甘油食用油干预对慢性代谢综合征合并无症状高尿酸血症患者的影响:多中心、前瞻性、双盲、随机对照试验的研究方案
本研究为多中心、前瞻性、双盲、随机对照试验,计划纳入176例慢性代谢综合征合并无症状高尿酸血症患者,随机分为A组(富含二酰甘油食用油,≥80%)和B组(富含三酰甘油的常规烹调油),干预12周,以血清尿酸水平为主要结局,评价疗效与安全性。
要点
- A组接受富含二酰甘油食用油(≥80%),B组接受富含三酰甘油的常规烹调油,干预12周。
- 主要结局为血清尿酸水平,次要结局包括空腹血糖、餐后2小时血糖、空腹胰岛素、糖化血红蛋白、血脂谱及颈动脉内中膜平均厚度。
- 每组样本量计算为88例,共176例。
核心结论
- 将评估富含二酰甘油的食用油与富含三酰甘油的常规烹调油相比,在慢性代谢综合征合并无症状高尿酸血症患者中的疗效与安全性,并推荐疗效更优、安全性更好的食用油供参考使用。
研究设计与样本
- 多中心、前瞻性、双盲、随机对照试验,计划纳入176例慢性代谢综合征合并无症状高尿酸血症患者,随机分为A组和B组,每组样本量计算为88例。
主要发现
- A组接受富含二酰甘油的食用油(≥80%),B组接受富含三酰甘油的常规烹调油,干预12周。
- 主要结局为血清尿酸水平;次要结局包括空腹血糖、餐后2小时血糖、空腹胰岛素、糖化血红蛋白、血脂谱及颈动脉内中膜平均厚度。
- 安全性评估包括血常规、尿常规、肝酶及心电图。
临床怎么用
- 作者计划根据试验结果推荐疗效更优、安全性更好的食用油供参考使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study is to evaluate the efficacy and safety of diacylglycerol (DAG) edible oil intervention in patients with chronic metabolic syndrome complicated by asymptomatic hyperuricemia through a multicenter, prospective, double-blind, randomized controlled clinical trial. METHODS: A multicenter, double-blind, and randomized controlled trial involving 176 patients was designed. All patients with chronic metabolic syndrome complicated by asymptomatic hyperuricemia who meet inclusion and exclusion criteria will be included in the study and will be randomized to either group A or group B. Group A will receive DAG-rich oil (≥ 80%) and group B will receive conventional cooking oil (triacylglycerol (TAG)-rich oil) for 12 weeks. Serum uric acid level is the primary outcome. Fasting blood glucose, 2 h postprandial blood glucose, fasting insulin, glycated hemoglobin, lipid profile, and average carotid intima-media thickness will be evaluated as the secondary outcomes. Blood routine, urine routine, liver enzymes, and electrocardiogram will be tested to assess the safety. The sample size for each group was calculated to be 88 cases. DISCUSSION: We will evaluate the efficacy and safety of DAG oil compared with conventional TAG oil in patients with chronic metabolic syndrome with asymptomatic hyperuricemia. The dietary oil with superior efficacy and better safety will be recommended for reference use. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2400085336. Registered on June 5, 2024.
引用
- Li GY, Zhu CF, Huang ZQ, et al. The effects of diacylglycerol edible oil intervention in patients with chronic metabolic syndrome combined with asymptomatic hyperuricemia: study protocol for a multicenter, prospective, double-blind, randomized controlled trial. Trials. 2025. PMID: 39806511. doi:10.1186/s13063-024-08638-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。